Syneos Health

Syneos Health's mission is to accelerate the successful delivery of new therapies to patients by reducing development and commercial risk for its biopharma clients. The company has achieved a remarkable track record, having helped develop or commercialize over 90% of novel drugs approved by the FDA and EMA in key therapeutic areas like oncology and CNS over the last five years. Its core strategy is built on a fully integrated, end-to-end service model that bridges the traditional gap between clinical development and commercialization, supported by a global team of over 26,000 professionals and a growing suite of AI and data-driven technology solutions.

SyneosHealth.ai, an integrated suite of AI, data analytics, and digital tools for clinical operations (e.g., StudyEngage, TME-Match) and commercial solutions (e.g., Kinetic, MODAL, Evolvics) designed to generate insights, improve performance, and reduce risk.

Syneos competes with large, pure-play CROs like IQVIA, ICON, and Labcorp in clinical research, and with major healthcare marketing networks like Publicis Health in commercial services. Its primary differentiator is its scaled, fully integrated model combining deep CRO and CCO capabilities under one roof, a structure few competitors have replicated.